Latest Hotspot

Auron Unveils Preliminary Findings on AUTX-703 for AML at ASH Conference

13 December 2024
2 min read

Auron Therapeutics, a biotech firm specializing in creating advanced targeted cancer treatments by targeting cancerous cell states, has released data on its primary project, AUTX-703, at the 66th ASH Annual Meeting and Exposition in San Diego, CA.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

During the ASH conference, Auron Therapeutics showcased AUTX-703's cell line activity, along with ex vivo and in vivo patient-derived xenograft (PDX) data. AUTX-703 is a potent, selective, and orally bioavailable heterobifunctional degrader of KAT2A/B, a histone acetyltransferase linked to AML and other cancers. The treatment was well-tolerated and facilitated cellular differentiation, leading to enhanced survival in a primary patient-derived orthotopic AML model. Auron plans to file several Investigational New Drug (IND) applications for AUTX-703 by the end of 2024, aiming to start clinical development in early 2025.

"AUTX-703's ability to degrade KAT2A/B and promote cellular differentiation, resulting in a significant survival benefit in a primary AML model, is a groundbreaking finding," stated Kate Yen, Ph.D., Founder and CEO of Auron. "These results underscore AURIGIN's platform's effectiveness in pinpointing promising oncology targets for various cancer types as we prepare to submit multiple INDs for AUTX-703 this year."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of December 13, 2024, there are 3 investigational drugs for the KAT2A and KAT2B target, including 5 indications, 2 R&D institutions involved,and as many as 97 patents.

AUTX-703 is a small molecule drug developed by Auron Therapeutics, Inc. The drug targets KAT2A and KAT2B and is currently in the preclinical phase of development. The therapeutic areas for AUTX-703 include neoplasms, hemic and lymphatic diseases, respiratory diseases, and urogenital diseases.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

Corbus Starts First Human Trial of CRB-601 for Solid Tumors
Latest Hotspot
2 min read
Corbus Starts First Human Trial of CRB-601 for Solid Tumors
12 December 2024
Corbus Pharmaceuticals Begins First Human Trial of CRB-601 for Advanced Solid Tumors, Marking First Patient Dosed.
Read →
siRNA and ASO: Exploring the Pillars of Small Nucleic Acid Therapeutics
Bio Sequence
7 min read
siRNA and ASO: Exploring the Pillars of Small Nucleic Acid Therapeutics
12 December 2024
siRNA (small interfering RNA) drugs and ASO (antisense oligonucleotide) drugs, as the two pillars of the small nucleic acid therapeutics field.
Read →
Solu Therapeutics Shares Promising Preclinical Results for STX-0712 in Leukemia at ASH
Latest Hotspot
3 min read
Solu Therapeutics Shares Promising Preclinical Results for STX-0712 in Leukemia at ASH
12 December 2024
Solu Therapeutics Reveals Favorable Preclinical Findings for STX-0712 in Treating Chronic Myelomonocytic and Acute Myeloid Leukemias at the ASH Conference.
Read →
Seismic Therapeutic Presents New Preclinical Results for S-1117 in Immune Thrombocytopenia at 66th ASH Meeting
Latest Hotspot
3 min read
Seismic Therapeutic Presents New Preclinical Results for S-1117 in Immune Thrombocytopenia at 66th ASH Meeting
12 December 2024
Seismic Therapeutic Unveils Fresh Preclinical Efficacy Results for S-1117 in Preventive and Treatment Animal Models of Immune Thrombocytopenia at the 66th ASH Meeting.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.